Table 1.
Patient characteristics
| Variables | Patients (N = 14) |
|---|---|
| Recipient age (y), mean (SD) | 56.5 (7.9) |
| Days between baseline and visit 2, mean (SD) | 33 (14) |
| Male, N (%) | 7 (50) |
| Immunosuppression | |
| Tacrolimus, N (%) | 11 (79) |
| Trough level, ng/mL, mean (SD) | 8.4 (3.1) |
| Cyclosporine, N (%) | 3 (21) |
| Trough level, ng/mL, mean (SD) | 64.0 (11.5) |
| Mycophenolate mofetil, N (%) | 9 (64) |
| Dose in mg per d, mean (SD) | 1,444 (391) |
| Mycophenolate sodium, N (%) | 5 (36) |
| Dose in mg per d, mean (SD) | 720 (441) |
| Glucocorticoids, N (%) | 14 (100) |
| Dose in mg Aprednislon per d, mean (SD) | 4 (1) |
| Number of grafts, median (IQR) | 1 (1‐2) |
| Time after transplantation (mo), mean (SD) | 69.4 (57.2) |
| PTDM duration (mo), mean (SD) | 68.1 (57.5) |
| PTDM onset after transplantation (mo), median (IQR) | 0.5 (0.0‐27.9) |
| Duration of insulin therapy (mo), mean (SD) | 55.4 (47.0) |
| Family history of diabetes, N (%) | 6 (43) |
| Hypertension, N (%) | 14 (100) |
| Cardiovascular comorbiditiesa, N (%) | 10 (71) |
| Antidiabetic agents | |
| Long‐acting insulin, N (%) | 8 (57) |
| Short‐acting insulin, N (%) | 4 (29) |
| Combination insulin, N (%) | 5 (43) |
| Oral antidiabetic drugs, N (%) | 3 (21) |
| Insulin, N (%) | 14 (100) |
| Dose in IU per d, mean (SD) | 27.2 (10.5) |
IQR, interquartile range; IU, international units; PTDM, posttransplantation diabetes mellitus; SD, standard deviation.
a
Cardiovascular comorbidities (at least 1 of the following): cerebrovascular disease or transient ischemic attack, coronary artery disease, peripheral vascular disease, cardiomyopathy or rhythm disorders, arterial or venous thrombosis.